Opiant Pharmaceuticals (NASDAQ: OPNT) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Analyst Ratings

This is a summary of current ratings and price targets for Opiant Pharmaceuticals and Alexion Pharmaceuticals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Opiant Pharmaceuticals 0 0 0 0 N/A
Alexion Pharmaceuticals 0 5 18 1 2.83

Alexion Pharmaceuticals has a consensus target price of $158.26, indicating a potential upside of 7.89%. Given Alexion Pharmaceuticals’ higher probable upside, analysts clearly believe Alexion Pharmaceuticals is more favorable than Opiant Pharmaceuticals.

Insider and Institutional Ownership

94.3% of Alexion Pharmaceuticals shares are owned by institutional investors. 63.8% of Opiant Pharmaceuticals shares are owned by insiders. Comparatively, 4.4% of Alexion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Opiant Pharmaceuticals and Alexion Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Opiant Pharmaceuticals $14.97 million 3.26 $5.99 million $2.54 9.49
Alexion Pharmaceuticals $3.41 billion 9.60 $1.34 billion $2.31 63.50

Alexion Pharmaceuticals has higher revenue and earnings than Opiant Pharmaceuticals. Opiant Pharmaceuticals is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Opiant Pharmaceuticals and Alexion Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Opiant Pharmaceuticals 38.89% 5,686.82% 87.49%
Alexion Pharmaceuticals 18.09% 7.47% 4.92%

Volatility & Risk

Opiant Pharmaceuticals has a beta of -0.75, meaning that its stock price is 175% less volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.4, meaning that its stock price is 40% more volatile than the S&P 500.

Summary

Alexion Pharmaceuticals beats Opiant Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Opiant Pharmaceuticals Company Profile

Opiant Pharmaceuticals, Inc., formerly Lightlake Therapeutics, Inc., is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA). The Company’s pipeline of product candidates includes a treatment for Binge Eating Disorder (BED), a treatment for Bulimia Nervosa (BN), a treatment for Cocaine Use Disorder (CocUD) and a heroin vaccine. The Company also is focused on other treatment opportunities.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous). Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS). PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system. Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP). Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). It is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

Receive News & Stock Ratings for Opiant Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.